BACKGROUND AND OBJECTIVE: There are several therapeutic options for patients with
myeiodysplastic syndrome (MDS) but most of them are poorly effective and the potentially …

PERSPECTIVE leukemia. The International Prognostic Scoring System (IPSS) 3—based on
the percentage of marrow blasts, the cytogenetic pattern, and the number and degree of …

The myelodysplastic syndromes (MDS) constitute a challenge for the biologist as well as for
the treating physician. In Section I, Dr. Willman reviews the current classifications and …

The myelodysplastic syndromes (MDS) are a group of clonal disorders, common especially
in the elderly, characterised by cytopenias and dysfunctional blood cells. They are a cause …

Background Allogeneic stem cell transplantation is usually considered the only curative
treatment option for patients with advanced or transformed myelodysplastic syndromes in …

Patients with myelodysplastic syndromes (MDS) suffer from pancytopenia and are at
substantial risk for progression to acute myeloid leukemia. The principal pathogenetic …

The available data fail to support a standard therapy for MDS. Any therapy should therefore,
include participation in a well designed clinical trial. The MDS include patients with a variety …

The myelodysplastic syndromes (MDS) are a group of clonal disorders characterized by one
or more cytopenias secondary to bone marrow dysfunction. The percentage of bone marrow …

Myelodysplastic syndrome (MDS) is a clonal disorder characterized by ineffective
hematopoiesis, which can lead to either fatal cytopenias or acute myelogenous leukemias …

The myelodysplastic syndromes (MDS) are a heterogeneous group of disorders
characterized by peripheral blood cytopenias with a hypercellular bone marrow exhibiting …